STONY BROOK N.Y., March 20, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and liquid biopsies for cancer diagnostics, announced today that it has signed a Research Agreement (the “Agreement”) with a global […]
– Assay under development uses PCR-based detection of viral sequences that code for the Spike protein that is also the target of the Company’s vaccine candidate with Takis Biotech –– messenger RNA abundance for Spike in host cells should yield high sensitivity – STONY BROOK, N.Y., March 19, 2020 – Applied DNA Sciences Inc. (NASDAQ: […]
STONY BROOK, N.Y., March 18, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”) today announced that its COVID-19 collaboration partner, Takis Biotech, a Rome, Italy-based a company focused on the development of cancer vaccines founded by scientists from Merck Research Laboratories, has received approval from the Italy’s Ministry of Health to begin a […]
A Stony Brook anti-counterfeiting company is seeking to adapt its DNA expertise to create a coronavirus vaccine with an Italian biotechnology partner. Applied DNA Sciences Inc. on Monday announced that it is expanding its alliance with Rome-based Takis Biotech on four potential vaccines to test on animals. In February, the companies announced a joint development […]
The PCR-produced linear DNA is expected to accelerate vaccine production. Applied DNA Sciences and Takis Biotech have designed four Covid-19 vaccine candidates to help protect against the novel coronavirus. The companies plan to manufacture the DNA vaccine candidates using PCR-based DNA (LinearDNA) manufacturing systems for preclinical testing in animals. Last month, Applied DNA Sciences subsidiary LineaRx […]
Driving the spike: The way COVID-19 attaches to host cells — and Applied DNA’s unique DNA-production abilities — could lead to a vaccine against the dreaded coronavirus. MARCH 2, 2020 By GREGORY ZELLER // Just weeks after announcing an expanded international collaboration targeting the menacing novel coronavirus, Applied DNA Sciences is preparing to mass-produce four potential vaccines. Leveraging the […]
STONY BROOK, N.Y., and ROME, ITALY – March 2, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and liquid biopsies for cancer diagnostics, and Takis Biotech (“Takis”), a company focused on the development of […]
By GREGORY ZELLERLook out, coronavirus – Applied DNA is coming for you. Adding to its growing portfolio of cutting-edge Polymerase Chain Reaction-based projects, Stony Brook-based Applied DNA Sciences is expanding its Joint Development Agreement with Italian R&D company Takis Biotech, with the headline-making 2019-nCoV in their sights. Already hot on the trail of new cancer vaccines, the partners will […]
The PCR-produced linear DNA is expected to accelerate vaccine production. Applied DNA Sciences has extended its partnership with Takis Biotech to include the development of a vaccine for 2019-nCoV coronavirus. LineaRx, a subsidiary of Applied DNA, will work with Takis Biotech on preclinical development of a linear DNA vaccine based on polymerase chain reaction (PCR). […]
Expanded Joint Development Agreement Serves as Basis for Preclinical Linear DNA Vaccine; Linear DNA Platform Will be the Production Framework STONY BROOK N.Y., February 7, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic […]